This phase 4 trial investigates the impact of prostate cancer treatment, specifically
androgen deprivation therapy (ADT, ie. leuprolide, relugolix), on the heart and coronary
vessels among men with localized, non-metastatic prostate cancer undergoing definitive
radiation therapy and concomitant ADT. Recently, the effect of hormone therapy that is
routinely used for prostate cancer on the heart has emerged as a concern, yet studies to
identify who is at risk and how damage to the heart may occur are lacking. Additionally, a
new hormone therapy drug, relugolix, has recently been Food and Drug Administration
(FDA)-approved and may reduce toxicity to the heart. This trial intends to investigate the
mechanism of cardiovascular toxicity from ADT, investigate the mechanism by which relugolix
reduces cardiovascular toxicity, and identify predictive biomarkers to improve individualized
risk-assessment for cardiovascular toxicity from hormone therapy.